- QMRO Home
- Barts Cancer Institute
- Centre for Molecular Oncology
- TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
Browse
Administrators only